{
    "root": "24fcd7b4-da33-4e24-bf31-3f1b5f51d800",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ELAPRASE",
    "value": "20250225",
    "ingredients": [
        {
            "name": "idursulfase",
            "code": "5W8JGG2651",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01271"
        },
        {
            "name": "sodium chloride",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "sodium phosphate, monobasic, monohydrate",
            "code": "593YOG76RN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "sodium phosphate, dibasic, heptahydrate",
            "code": "70WT22SF4B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "polysorbate 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        }
    ],
    "indications": {
        "text": "elaprase indicated patients hunter syndrome ( mucopolysaccharidosis ii , mps ii ) . elaprase shown improve walking capacity patients 5 years older . patients 16 months 5 years age , data available demonstrate improvement disease-related symptoms long term outcome ; however , treatment elaprase reduced spleen volume similarly adults children 5 years age older . safety efficacy elaprase established pediatric patients less 16 months age [ ( 8.4 ) ] .",
        "doid_entities": [
            {
                "text": "hunter syndrome (DOID:12799)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12799"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "mucopolysaccharidosis (DOID:12798)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12798"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended 0.5 mg per kg body weight administered every week intravenous infusion ( 2 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "elaprase supplied sterile injection 5 ml type glass vial . vials closed butyl rubber stopper fluororesin coating aluminum overseal blue flip-off plastic cap . carton contains single vial ndc 54092-700-01",
    "adverseReactions": "none .",
    "indications_original": "ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older.\n                  In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older.\n                  The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age [see Use in Specific Populations (8.4)].",
    "contraindications_original": "The recommended dosage is 0.5 mg per kg of body weight administered once every week as an intravenous infusion ( 2 ).",
    "warningsAndPrecautions_original": "ELAPRASE is supplied as a sterile injection in a 5 mL Type I glass vial. The vials are closed with a butyl rubber stopper with fluororesin coating and an aluminum overseal with a blue flip-off plastic cap.\n                  Each carton contains a single vial \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 NDC 54092-700-01",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "ELAPRASE",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01271"
        }
    ]
}